Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Finding, Prospective, Multi Center, Randomized, Parallel Group Study to Assess the Efficacy and Safety of Three Different Dose Levels of AVI 014 (G-CSF) Compared With a Standard Dose of Neupogen® in Breast Cancer Patients at High (>20%) Risk for Chemotherapy Induced Severe Neutropenia

NCT00497809 is registered in ClinicalTrials.gov with AviGenics as lead sponsor.

NCT NCT00497809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00497809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Finding, Prospective, Multi Center, Randomized, Parallel Group Study to Assess the Efficacy and Safety of Three Different Dose Levels of AVI 014 (G-CSF) Compared With a Standard Dose of Neupogen® in Breast Cancer Patients at High (>20%) Risk for Chemotherapy Induced Severe Neutropenia
Lead sponsor
AviGenics
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
July 31, 2009
Enrollment
189 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, neutropenia